TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03542201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLS
Description: Participants will have to read standard textual information about the conducted systematic review (approximately 500 words)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blogshot
Description: Participants will have to read the blogshot information about the results of the Cochrane systematic review (approximately 100 words)
Study: NCT00654498

Intervention type: DRUG
Group type: OTHER
Intervention: Pramipexole

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT02752100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty
Study: NCT03056573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transaortic TAVR Implant
Description: Transaortic TAVR implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subclavian /Axillary TAVR implant
Description: Subclavian /Axillary TAVR implant
Study: NCT01050400

Intervention type: GENETIC
Intervention: Cytochrome P450 2D6 (CYP2D6) genetic screening.
Description: Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.

Intervention type: GENETIC
Intervention: Cytochrome P450 2D6 (CYP2D6) genetic screening.
Description: Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.
Study: NCT00695565

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: TID x 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine Topical Gel (ARC-4558)
Description: TID x 12 weeks
Study: NCT03183362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barbed suture ( STRATAFIX™ )
Description: Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional suture (VICRYL™)
Description: Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures .
Study: NCT03382574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingo-Oophorectomy
Description: Undergo risk-reducing salpingo-oophorectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salpingo-Oophorectomy
Description: Undergo risk-reducing salpingo-oophorectomy
Study: NCT01648231

Intervention type: DRUG
Group type: OTHER
Intervention: Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
Description: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state

Intervention type: DRUG
Group type: OTHER
Intervention: Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
Description: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state

Intervention type: DRUG
Group type: OTHER
Intervention: Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
Description: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
Study: NCT00262431

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheostomy on day 3-5 in early group and 10-12 in late group
Description: Upon admission to ICU, acute respiratory failure patients requiring at least 3 days of mechanical ventilation and defined by a SAPS II score between 35 and 65, will be randomly assigned to either arm A or B of the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheostomy on day 3-5 in early group and 10-12 in late group
Description: Upon admission to ICU, acute respiratory failure patients requiring at least 3 days of mechanical ventilation and defined by a SAPS II score between 35 and 65, will be randomly assigned to either arm A or B of the study.
Study: NCT01531842

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conj flora Antibiotic resistance
Description: Patients will either receive a drop of topical antibiotic before and after the intravitral injection or no topical antibiotics (only typical prep with betadine).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conj flora Antibiotic resistance
Description: Patients will either receive a drop of topical antibiotic before and after the intravitral injection or no topical antibiotics (only typical prep with betadine).
Study: NCT03583190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical-cranial dry needling
Description: Segmental needling of the neck and needling in the patient's headache distribution. Peripherally sensitized areas of the neck may also be dry needled based on the findings of the clinical evaluation.
Study: NCT02339337

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abbreviation of treatment duration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abbreviation of treatment duration
Study: NCT04387968

Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 presto test
Description: Use an auto-test in 15 minutes get the results about covid-19 anticorps

Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 presto test
Description: Use an auto-test in 15 minutes get the results about covid-19 anticorps
Study: NCT01762787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin solution
Description: 5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cantharidin solution
Description: 5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin solution
Description: 5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to aspirin
Description: 0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to prednisolone
Description: 0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
Study: NCT01785901

Intervention type: OTHER
Intervention: without interventions
Description: without interventions
Study: NCT00115388

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Screening for chlamydia using self-taken vaginal swabs
Description: Women in the intervention group will be tested for chlamydia and those found to be infected will be referred for treatment and partner notification
Study: NCT00765076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' influenza vaccine GSK2186877A
Description: One intramuscular injection at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Fluarix
Description: One intramuscular injection at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Fluarix
Description: One intramuscular injection at Day 0
Study: NCT02069314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Description: subjects are asked to consume a smoothie with whey protein added

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate (polycose) supplementation
Description: Subjects are asked to consume a beverage with polycose added
Study: NCT01811719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced NFP (NFP+)
Description: Women in the experimental group received three possible interventions. First they received regular and periodic structured intimate partner violence (IPV) assessments from their nurse. Those who indicted any IPV - whether physical violence or emotional abuse or controlling behavior - were then given the Parker-McFarlane Brochure Intervention. Finally, all women were provided the Markman and Stanley Within My Reach curriculum according to their needs and interests.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NFP as usual
Description: The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
Study: NCT02193295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction
Description: Dietary intervention to reduce lipid content in liver and muscle with minimal overall weight loss. Weekly visits for measurements of body weight, body composition, blood glucose and MRS measurements of liver and muscle lipid.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction
Description: Dietary intervention to reduce lipid content in liver and muscle with minimal overall weight loss. Weekly visits for measurements of body weight, body composition, blood glucose and MRS measurements of liver and muscle lipid.
Study: NCT03821597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sequential compression devices (SCDs)
Description: Application of sequential compression devices in surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No sequential compression.
Description: No sequential compression devices are applied.
Study: NCT04344444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: tablets provided as described in Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: tablets provided as described in Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: tablets provided as described in Arm C
Study: NCT00768053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg once a week
Study: NCT02335944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: In the Phase 1, capmatinib was administered orally, twice per day, at a dose of 200 mg or 400 mg, in fasted state.~In the Phase II, participants received capmatinib at the RP2D (400 mg twice per day) in fasted state (Groups 1, 2 and 3) or fed state (Group 4).~Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: In the Phase 1, capmatinib was administered orally, twice per day, at a dose of 200 mg or 400 mg, in fasted state.~In the Phase II, participants received capmatinib at the RP2D (400 mg twice per day) in fasted state (Groups 1, 2 and 3) or fed state (Group 4).~Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: In the Phase 1, capmatinib was administered orally, twice per day, at a dose of 200 mg or 400 mg, in fasted state.~In the Phase II, participants received capmatinib at the RP2D (400 mg twice per day) in fasted state (Groups 1, 2 and 3) or fed state (Group 4).~Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).
Study: NCT01379144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost 125 ug
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 50 ug
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
Study: NCT00233883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide [Fuzeon]
Description: 90mg sc bid by Biojector 2000 NFID for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enfuvirtide [Fuzeon]
Description: 90mg sc bid by 27G1/2 needle/syringe for 4 weeks
Study: NCT02335944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: In the Phase 1, capmatinib was administered orally, twice per day, at a dose of 200 mg or 400 mg, in fasted state.~In the Phase II, participants received capmatinib at the RP2D (400 mg twice per day) in fasted state (Groups 1, 2 and 3) or fed state (Group 4).~Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: In the Phase 1, capmatinib was administered orally, twice per day, at a dose of 200 mg or 400 mg, in fasted state.~In the Phase II, participants received capmatinib at the RP2D (400 mg twice per day) in fasted state (Groups 1, 2 and 3) or fed state (Group 4).~Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: In the Phase 1, capmatinib was administered orally, twice per day, at a dose of 200 mg or 400 mg, in fasted state.~In the Phase II, participants received capmatinib at the RP2D (400 mg twice per day) in fasted state (Groups 1, 2 and 3) or fed state (Group 4).~Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nazartinib
Description: In the Phase 1, nazartinib was administered orally, once a day, at a dose of 50 mg, 75 mg, 100 mg or 150 mg in fasted state.~In the Phase II, participants received nazartinib at the RP2D (100 mg once daily) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nazartinib
Description: In the Phase 1, nazartinib was administered orally, once a day, at a dose of 50 mg, 75 mg, 100 mg or 150 mg in fasted state.~In the Phase II, participants received nazartinib at the RP2D (100 mg once daily) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).
Study: NCT02073344

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy
Description: intermittent hemodialysis or peritoneal dialysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: no renal replacement therapy
Study: NCT01702493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cap SRT2104
Description: Micronized free base in a 250 mg SRT2104 (active equivalents) capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab SRT2104 slow release
Description: New 250 mg SRT2104 mesylate salt slow release tablet
Study: NCT02335944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nazartinib
Description: In the Phase 1, nazartinib was administered orally, once a day, at a dose of 50 mg, 75 mg, 100 mg or 150 mg in fasted state.~In the Phase II, participants received nazartinib at the RP2D (100 mg once daily) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nazartinib
Description: In the Phase 1, nazartinib was administered orally, once a day, at a dose of 50 mg, 75 mg, 100 mg or 150 mg in fasted state.~In the Phase II, participants received nazartinib at the RP2D (100 mg once daily) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nazartinib
Description: In the Phase 1, nazartinib was administered orally, once a day, at a dose of 50 mg, 75 mg, 100 mg or 150 mg in fasted state.~In the Phase II, participants received nazartinib at the RP2D (100 mg once daily) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nazartinib
Description: In the Phase 1, nazartinib was administered orally, once a day, at a dose of 50 mg, 75 mg, 100 mg or 150 mg in fasted state.~In the Phase II, participants received nazartinib at the RP2D (100 mg once daily) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).
Study: NCT03342729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants receive the AMP 10-week program immediately

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will not received the AMP 10-week program immediately, rather will wait 3-months
Study: NCT01702493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab SRT2104 intermediate release
Description: New 250 mg SRT2104 mesylate salt intermediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab SRT2104 fast release
Description: New 250 mg SRT2104 mesylate salt fast release tablet
Study: NCT03424642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive 4D-ultrasound examination
Description: Randomized controlled trial
Study: NCT01719328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vinyasa yoga
Study: NCT01675726

Intervention type: OTHER
Group type: OTHER
Intervention: questionary on quality of life
Study: NCT01702493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selected formulations of SRT2104 from Part 1
Description: SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selected formulations of SRT2104 from Part 1
Description: SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selected formulations of SRT2104 from Part 1 single alternative dose
Description: SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1
Study: NCT04050605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A toric contact lens
Description: Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A toric contact lens
Description: Contact Lens
Study: NCT04248179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Ropivacaine 5mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Saline 0.9%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil and PONV prophylaxis
Description: 30 minutes prior to emergence 0.2 μg/kg total body weight Sufentanil IV and 1 gram of paracetamol IV (if 6hrs since preoperative medicine) and 4 mg ondansetron IV (PONV prophylaxis) will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil and PONV prophylaxis
Description: 30 minutes prior to emergence 0.2 μg/kg total body weight Sufentanil IV and 1 gram of paracetamol IV (if 6hrs since preoperative medicine) and 4 mg ondansetron IV (PONV prophylaxis) will be administered.
Study: NCT03619525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lung recruitment
Description: During bypass, patients in this group will receive a lung protective design in the form of continuous positive airway pressure (CPAP) by closing APL valve at pressure of 5 Cm H2o combined with intermittent recruitment by sustained manual lung inflation at a pressure of 35 cmH2O for 30 seconds every (30-40) minute